BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luebker SA, Koepsell SA. Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies. Front Oncol 2019;9:268. [PMID: 31058079 DOI: 10.3389/fonc.2019.00268] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 Tanaka Y, Murata M, Shen CH, Furue M, Ito T. NECTIN4: A Novel Therapeutic Target for Melanoma. Int J Mol Sci 2021;22:976. [PMID: 33478111 DOI: 10.3390/ijms22020976] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
2 Sahin I, George A, Seyhan AA. Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers. Int J Mol Sci 2021;22:11790. [PMID: 34769221 DOI: 10.3390/ijms222111790] [Reference Citation Analysis]
3 Tabbò F, Pisano C, Mazieres J, Mezquita L, Nadal E, Planchard D, Pradines A, Santamaria D, Swalduz A, Ambrogio C, Novello S, Ortiz-cuaran S. How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC). Cancer Treatment Reviews 2022;103:102335. [DOI: 10.1016/j.ctrv.2021.102335] [Reference Citation Analysis]
4 Yeom H, Hwang SH, Han BI, Lee M. Differential Sensitivity of Wild-Type and BRAF-Mutated Cells to Combined BRAF and Autophagy Inhibition. Biomol Ther (Seoul) 2021;29:434-44. [PMID: 33551379 DOI: 10.4062/biomolther.2020.203] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Catalani E, Giovarelli M, Zecchini S, Perrotta C, Cervia D. Oxidative Stress and Autophagy as Key Targets in Melanoma Cell Fate. Cancers (Basel) 2021;13:5791. [PMID: 34830947 DOI: 10.3390/cancers13225791] [Reference Citation Analysis]
6 Ernst M, Giubellino A. The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma. Biomedicines 2022;10:822. [DOI: 10.3390/biomedicines10040822] [Reference Citation Analysis]
7 Bilska B, Schedel F, Piotrowska A, Stefan J, Zmijewski M, Pyza E, Reiter RJ, Steinbrink K, Slominski AT, Tulic MK, Kleszczyński K. Mitochondrial function is controlled by melatonin and its metabolites in vitro in human melanoma cells. J Pineal Res 2021;70:e12728. [PMID: 33650175 DOI: 10.1111/jpi.12728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Lin Y, Liu J, Chang Y, Yu C, Yi W, Lane H, Lu C. Predicting Anticancer Drug Resistance Mediated by Mutations. Pharmaceuticals 2022;15:136. [DOI: 10.3390/ph15020136] [Reference Citation Analysis]
9 Lelliott EJ, McArthur GA, Oliaro J, Sheppard KE. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. Front Immunol 2021;12:661737. [PMID: 34025662 DOI: 10.3389/fimmu.2021.661737] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Hamid AB, Petreaca RC. Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. Cancers (Basel) 2020;12:E927. [PMID: 32283832 DOI: 10.3390/cancers12040927] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Kawahara B, Faull KF, Janzen C, Mascharak PK. Carbon Monoxide Inhibits Cytochrome P450 Enzymes CYP3A4/2C8 in Human Breast Cancer Cells, Increasing Sensitivity to Paclitaxel. J Med Chem 2021;64:8437-46. [PMID: 34097831 DOI: 10.1021/acs.jmedchem.1c00404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Vasudevan S, Flashner-Abramson E, Alkhatib H, Roy Chowdhury S, Adejumobi IA, Vilenski D, Stefansky S, Rubinstein AM, Kravchenko-Balasha N. Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations. NPJ Precis Oncol 2021;5:50. [PMID: 34112933 DOI: 10.1038/s41698-021-00190-3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Imlimthan S, Khng YC, Keinänen O, Zhang W, Airaksinen AJ, Kostiainen MA, Zeglis BM, Santos HA, Sarparanta M. A Theranostic Cellulose Nanocrystal-Based Drug Delivery System with Enhanced Retention in Pulmonary Metastasis of Melanoma. Small 2021;17:e2007705. [PMID: 33738957 DOI: 10.1002/smll.202007705] [Reference Citation Analysis]
14 Jiao D, Yang S. Overcoming Resistance to Drugs Targeting KRASG12C Mutation. Innovation (N Y). 2020;1. [PMID: 32939510 DOI: 10.1016/j.xinn.2020.100035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
15 Czarnecka AM, Bartnik E, Fiedorowicz M, Rutkowski P. Targeted Therapy in Melanoma and Mechanisms of Resistance. Int J Mol Sci 2020;21:E4576. [PMID: 32605090 DOI: 10.3390/ijms21134576] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
16 Bonnal SC, López-Oreja I, Valcárcel J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nat Rev Clin Oncol 2020;17:457-74. [PMID: 32303702 DOI: 10.1038/s41571-020-0350-x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 35.0] [Reference Citation Analysis]
17 Lu Y, Liu B, Liu Y, Yu X, Cheng G. Dual effects of active ERK in cancer: A potential target for enhancing radiosensitivity. Oncol Lett 2020;20:993-1000. [PMID: 32724338 DOI: 10.3892/ol.2020.11684] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
18 van Dorst DCH, Dobbin SJH, Neves KB, Herrmann J, Herrmann SM, Versmissen J, Mathijssen RHJ, Danser AHJ, Lang NN. Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. Circ Res 2021;128:1040-61. [PMID: 33793337 DOI: 10.1161/CIRCRESAHA.121.318051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Jandova J, Wondrak GT. Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAFV600E/NRASQ61K Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model. J Invest Dermatol 2021:S0022-202X(21)02368-X. [PMID: 34687745 DOI: 10.1016/j.jid.2021.10.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Lee S, Rauch J, Kolch W. Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity. Int J Mol Sci 2020;21:E1102. [PMID: 32046099 DOI: 10.3390/ijms21031102] [Cited by in Crossref: 68] [Cited by in F6Publishing: 76] [Article Influence: 34.0] [Reference Citation Analysis]
21 Feddersen CR, Schillo JL, Varzavand A, Vaughn HR, Wadsworth LS, Voigt AP, Zhu EY, Jennings BM, Mullen SA, Bobera J, Riordan JD, Stipp CS, Dupuy AJ. Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma. Cancer Res 2019;79:5074-87. [PMID: 31416844 DOI: 10.1158/0008-5472.CAN-19-0244] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
22 Nawrot-Hadzik I, Choromańska A, Abel R, Preissner R, Saczko J, Matkowski A, Hadzik J. Cytotoxic Effect of Vanicosides A and B from Reynoutria sachalinensis Against Melanotic and Amelanotic Melanoma Cell Lines and in silico Evaluation for Inhibition of BRAFV600E and MEK1. Int J Mol Sci 2020;21:E4611. [PMID: 32610527 DOI: 10.3390/ijms21134611] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
23 Radaszkiewicz T, Nosková M, Gömöryová K, Vondálová Blanářová O, Radaszkiewicz KA, Picková M, Víchová R, Gybeľ T, Kaiser K, Demková L, Kučerová L, Bárta T, Potěšil D, Zdráhal Z, Souček K, Bryja V. RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy. Elife 2021;10:e65759. [PMID: 34702444 DOI: 10.7554/eLife.65759] [Reference Citation Analysis]
24 Montoya S, Soong D, Nguyen N, Affer M, Munamarty SP, Taylor J. Targeted Therapies in Cancer: To Be or Not to Be, Selective. Biomedicines 2021;9:1591. [PMID: 34829820 DOI: 10.3390/biomedicines9111591] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Soumoy L, Schepkens C, Krayem M, Najem A, Tagliatti V, Ghanem GE, Saussez S, Colet JM, Journe F. Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis. Cancers (Basel) 2020;12:E1323. [PMID: 32455924 DOI: 10.3390/cancers12051323] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Oppel F, Görner M, Sudhoff H. The Potential of Tumor Debulking to Support Molecular Targeted Therapies. Front Oncol 2020;10:801. [PMID: 32626653 DOI: 10.3389/fonc.2020.00801] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Serpa J. Metabolic Remodeling as a Way of Adapting to Tumor Microenvironment (TME), a Job of Several Holders. Adv Exp Med Biol 2020;1219:1-34. [PMID: 32130691 DOI: 10.1007/978-3-030-34025-4_1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
28 Huang C, Radi RH, Arbiser JL. Mitochondrial Metabolism in Melanoma. Cells 2021;10:3197. [PMID: 34831420 DOI: 10.3390/cells10113197] [Reference Citation Analysis]
29 Sabbah M, Najem A, Krayem M, Awada A, Journe F, Ghanem GE. RTK Inhibitors in Melanoma: From Bench to Bedside. Cancers (Basel) 2021;13:1685. [PMID: 33918490 DOI: 10.3390/cancers13071685] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
30 Hamis SJ, Kapelyukh Y, McLaren A, Henderson CJ, Roland Wolf C, Chaplain MAJ. Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling. Br J Cancer 2021;125:1552-60. [PMID: 34621046 DOI: 10.1038/s41416-021-01565-w] [Reference Citation Analysis]
31 Jung H, Bae K, Lee JY, Kim JH, Han HJ, Yoon HY, Yoon KA. Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target. Int J Mol Sci 2021;22:9151. [PMID: 34502061 DOI: 10.3390/ijms22179151] [Reference Citation Analysis]
32 Czyz M. Fibroblast Growth Factor Receptor Signaling in Skin Cancers. Cells 2019;8:E540. [PMID: 31167513 DOI: 10.3390/cells8060540] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
33 Olmeda D, Cerezo-Wallis D, Mucientes C, Calvo TG, Cañón E, Alonso-Curbelo D, Ibarz N, Muñoz J, Rodriguez-Peralto JL, Ortiz-Romero P, Ortega S, Soengas MS. Live imaging of neolymphangiogenesis identifies acute antimetastatic roles of dsRNA mimics. EMBO Mol Med 2021;13:e12924. [PMID: 34762341 DOI: 10.15252/emmm.202012924] [Reference Citation Analysis]
34 Hartman ML, Rogut M, Mielczarek-Lewandowska A, Wozniak M, Czyz M. 17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines. Int J Mol Sci 2020;21:E3749. [PMID: 32466509 DOI: 10.3390/ijms21113749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Yang C, Tian C, Hoffman TE, Jacobsen NK, Spencer SL. Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling. Nat Commun 2021;12:1747. [PMID: 33741929 DOI: 10.1038/s41467-021-21549-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
36 Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T, Yang S. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 2021;6:201. [PMID: 34054126 DOI: 10.1038/s41392-021-00572-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Goh CJH, Wong JH, El Farran C, Tan BX, Coffill CR, Loh YH, Lane D, Arumugam P. Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen. G3 (Bethesda) 2021;11:jkaa069. [PMID: 33604667 DOI: 10.1093/g3journal/jkaa069] [Reference Citation Analysis]
38 Giblin W, Bringman-Rodenbarger L, Guo AH, Kumar S, Monovich AC, Mostafa AM, Skinner ME, Azar M, Mady AS, Chung CH, Kadambi N, Melong KA, Lee HJ, Zhang L, Sajjakulnukit P, Trefely S, Varner EL, Iyer S, Wang M, Wilmott JS, Soyer HP, Sturm RA, Pritchard AL, Andea AA, Scolyer RA, Stark MS, Scott DA, Fullen DR, Bosenberg MW, Chandrasekaran S, Nikolovska-Coleska Z, Verhaegen ME, Snyder NW, Rivera MN, Osterman AL, Lyssiotis CA, Lombard DB. The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics. J Clin Invest 2021;131:138926. [PMID: 33945506 DOI: 10.1172/JCI138926] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Yeom H, Hwang S, Kim H, Lee M. Increase in the sensitivity to PLX4720 through inhibition of transcription factor EB-dependent autophagy in BRAF inhibitor-resistant cells. Toxicol Res 2022;38:35-44. [DOI: 10.1007/s43188-021-00109-x] [Reference Citation Analysis]
40 Schäfer A, Haenig B, Erupathil J, Strickner P, Sabato D, Welford RWD, Klaeylé L, Simon E, Krepler C, Brafford P, Xiao M, Herlyn M, Gstaiger M, Lehembre F, Renz I. Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma. Oncogene 2021;40:1659-73. [PMID: 33500549 DOI: 10.1038/s41388-020-01628-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
41 Nguyen HT, Phung CD, Tran TH, Pham TT, Pham LM, Nguyen TT, Jeong JH, Choi HG, Ku SK, Yong CS, Kim JO. Manipulating immune system using nanoparticles for an effective cancer treatment: Combination of targeted therapy and checkpoint blockage miRNA. J Control Release 2021;329:524-37. [PMID: 32971203 DOI: 10.1016/j.jconrel.2020.09.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
42 Loureiro JB, Abrantes M, Oliveira PA, Saraiva L. P53 in skin cancer: From a master player to a privileged target for prevention and therapy. Biochim Biophys Acta Rev Cancer 2020;1874:188438. [PMID: 32980466 DOI: 10.1016/j.bbcan.2020.188438] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
43 Mazurkiewicz J, Simiczyjew A, Dratkiewicz E, Ziętek M, Matkowski R, Nowak D. Stromal Cells Present in the Melanoma Niche Affect Tumor Invasiveness and Its Resistance to Therapy. Int J Mol Sci 2021;22:E529. [PMID: 33430277 DOI: 10.3390/ijms22020529] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
44 Rizzolio S, Corso S, Giordano S, Tamagnone L. Autocrine Signaling of NRP1 Ligand Galectin-1 Elicits Resistance to BRAF-Targeted Therapy in Melanoma Cells. Cancers (Basel) 2020;12:E2218. [PMID: 32784465 DOI: 10.3390/cancers12082218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Ji Z, Njauw CN, Guhan S, Kumar R, Reddy B, Rajadurai A, Flaherty K, Tsao H. Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition. J Invest Dermatol 2021;141:1317-1324.e1. [PMID: 33159968 DOI: 10.1016/j.jid.2020.06.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Niitsu Y, Sato Y, Takayama T. Implications of glutathione-S transferase P1 in MAPK signaling as a CRAF chaperone: In memory of Dr. Irving Listowsky. Proc Jpn Acad Ser B Phys Biol Sci 2022;98:72-86. [PMID: 35153270 DOI: 10.2183/pjab.98.005] [Reference Citation Analysis]
47 Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther 2021;6:386. [PMID: 34776511 DOI: 10.1038/s41392-021-00780-4] [Reference Citation Analysis]
48 Chacon AC, Melucci AD, Qin SS, Prieto PA. Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma. Int J Mol Sci 2021;22:3228. [PMID: 33810078 DOI: 10.3390/ijms22063228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
49 Lee KH, Goh J, Kim YJ, Kim K. Identification of synthetic chemosensitivity genes paired with BRAF for BRAF/MAPK inhibitors. Sci Rep 2020;10:20001. [PMID: 33203961 DOI: 10.1038/s41598-020-76909-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Zerfaoui M, Dokunmu TM, Toraih EA, Rezk BM, Abd Elmageed ZY, Kandil E. New Insights into the Link between Melanoma and Thyroid Cancer: Role of Nucleocytoplasmic Trafficking. Cells 2021;10:367. [PMID: 33578751 DOI: 10.3390/cells10020367] [Reference Citation Analysis]
51 Nguyen MT, Lin CH, Liu SM, Miyashita A, Ihn H, Lin H, Ng CH, Tsai JC, Chen MH, Tsai MS, Lin IY, Liu SC, Li LY, Fukushima S, Lu J, Ma N. miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma. Neoplasia 2020;22:789-99. [PMID: 33142243 DOI: 10.1016/j.neo.2020.10.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Howden K, Chapman S, Serletis D, Kazina C, Rafay MF, Faury D, Hazrati L, Jabado N, Vanan MI. Management of Inoperable Supra-Sellar Low-Grade Glioma With BRAF Mutation in Young Children. Cureus. [DOI: 10.7759/cureus.19400] [Reference Citation Analysis]
53 Kleszczyński K, Böhm M. Can melatonin and its metabolites boost the efficacy of targeted therapy in patients with advanced melanoma? Exp Dermatol 2020;29:860-3. [DOI: 10.1111/exd.14144] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Hartman ML, Gajos-Michniewicz A, Talaj JA, Mielczarek-Lewandowska A, Czyz M. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells. Cancer Lett 2021;499:122-36. [PMID: 33259900 DOI: 10.1016/j.canlet.2020.11.036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Liu L, Yue Q, Ma J, Liu Y, Zhao T, Guo W, Zhu G, Guo S, Wang S, Gao T, Li C, Shi Q. POU4F1 promotes the resistance of melanoma to BRAF inhibitors through MEK/ERK pathway activation and MITF up-regulation. Cell Death Dis 2020;11:451. [PMID: 32532957 DOI: 10.1038/s41419-020-2662-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
56 Hartman ML. Non-Apoptotic Cell Death Signaling Pathways in Melanoma. Int J Mol Sci 2020;21:E2980. [PMID: 32340261 DOI: 10.3390/ijms21082980] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
57 Motti ML, Minopoli M, Di Carluccio G, Ascierto PA, Carriero MV. MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors. Int J Mol Sci 2020;21:E4544. [PMID: 32604720 DOI: 10.3390/ijms21124544] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
58 Wells JD, Griffin JR, Miller TW. Pan-Cancer Transcriptional Models Predicting Chemosensitivity in Human Tumors. Cancer Inform 2021;20:11769351211002494. [PMID: 33795931 DOI: 10.1177/11769351211002494] [Reference Citation Analysis]
59 Li J, Long J, Zhang J, Liu N, Yan B, Tang L, Chen X, Peng C. Novel chloroquine derivative suppresses melanoma cell growth by DNA damage through increasing ROS levels. J Cell Mol Med 2022. [PMID: 35332658 DOI: 10.1111/jcmm.17260] [Reference Citation Analysis]
60 Raineri A, Fasoli S, Campagnari R, Gotte G, Menegazzi M. Onconase Restores Cytotoxicity in Dabrafenib-Resistant A375 Human Melanoma Cells and Affects Cell Migration, Invasion and Colony Formation Capability. Int J Mol Sci 2019;20:E5980. [PMID: 31783660 DOI: 10.3390/ijms20235980] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
61 Emran AA, Tseng H, Gunatilake D, Cook SJ, Ahmed F, Wang S, Hersey P, Gallagher SJ, Tiffen JC. A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma. Journal of Investigative Dermatology 2021;141:2238-2249.e12. [DOI: 10.1016/j.jid.2020.12.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Loureiro JB, Raimundo L, Calheiros J, Carvalho C, Barcherini V, Lima NR, Gomes C, Almeida MI, Alves MG, Costa JL, Santos MMM, Saraiva L. Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance. Cancers (Basel) 2021;13:1648. [PMID: 33916029 DOI: 10.3390/cancers13071648] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Patel H, Mishra R, Yacoub N, Alanazi S, Kilroy MK, Garrett JT. IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma. Cancers (Basel) 2021;13:5863. [PMID: 34831014 DOI: 10.3390/cancers13225863] [Reference Citation Analysis]
64 Wei Y, Jiang Z, Lu J. USP22 promotes melanoma and BRAF inhibitor resistance via YAP stabilization. Oncol Lett 2021;21:394. [PMID: 33777217 DOI: 10.3892/ol.2021.12655] [Reference Citation Analysis]
65 Chen Y, Li H, Zhang G, Wu Y, Xiao J, Liu J, Qiu P, Liu X, Sun L, Du B, Tan Y. Synergistic inhibitory effect of resveratrol and TK/GCV therapy on melanoma cells. J Cancer Res Clin Oncol 2020;146:1489-99. [PMID: 32246216 DOI: 10.1007/s00432-020-03203-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]